Adial Pharmaceuticals, Inc. announced on January 18, 2024, the appointment of Tony Goodman as the company's Chief Operating Officer (COO). Goodman, a seasoned executive in the pharmaceutical industry and a member of Adial's Board of Directors since 2017, will be responsible for overseeing strategic growth initiatives, including clinical development and commercial planning for AD04, Adial's lead investigational drug for alcohol use disorder (AUD). He will also focus on business development initiatives aimed at partnership opportunities in addiction treatment. Goodman's appointment follows his agreement to serve as COO under a Statement of Work #2 to the Master Services Agreement with The Keswick Group, LLC, which he founded. He will receive a monthly compensation of $25,000 and will dedicate at least 75% of his business...Show More

Adial Pharmaceuticals, Inc. announced on January 18, 2024, the appointment of Tony Goodman as the company's Chief Operating Officer (COO). Goodman, a seasoned executive in the pharmaceutical industry and a member of Adial's Board of Directors since 2017, will be responsible for overseeing strategic growth initiatives, including clinical development and commercial planning for AD04, Adial's lead investigational drug for alcohol use disorder (AUD). He will also focus on business development initiatives aimed at partnership opportunities in addiction treatment. Goodman's appointment follows his agreement to serve as COO under a Statement of Work #2 to the Master Services Agreement with The Keswick Group, LLC, which he founded. He will receive a monthly compensation of $25,000 and will dedicate at least 75% of his business time to the role. The press release emphasizes Goodman's extensive experience and successful track record, particularly in the addiction space, as Adial advances the AD04 clinical program and prepares for potential commercialization. Goodman's previous roles include leadership positions at Indivior PLC and Reckitt Benckiser Pharmaceuticals, where he contributed to significant revenue growth in the addiction market.